

Healthcare / Medical companies have become a point of significant focus over the course of the past 18 months and for good reason, considering the sort of damage that was wreaked on society by the Covid -19, Alzheimers, PTSD and Traumatic Encephalopathy. Many companies have managed to come to light during this period but at this point in time, it is important for investors to search for companies that may acquire cutting edge technologies .

Hence, it might now be the right time to take close look at **Halberd Corporation (OTCMKTS: HALB)**, a company that has and is currently developing treatments for a wide range of diseases and acquiring patents for such.

About Halberd Corporation

First, it is necessary for investors to have an idea about the aims and business structure of Halberd before going into more details. Halberd Corporation is specifically looking to develop treatments that can cure disease throughout the world and in collaboration with Youngstown State University and Arizona State University develop safe and successful treatments for such diseases as .Alzheimer's, PTSD, and Chronic Traumatic Encephalopathy. Halberd proposes treatments that include the cleansing bodily fluids through extra-corporeal laser methodology.

This may serve as the first step to an elegant solution to these worldwide tragedies More importantly, Halberd Corporation is working on many treatments for serious global health issues such as making HALB a compelling investment opportunity at this point.

It is also necessary to note that Halberd Corporation is a fully reporting company to the United States Securities and Exchange Commission and its stock is currently listed on the OTC PINK Markets. Perhaps the most important aspect of any company involved in an innovation-driven sector like healthcare is the portfolio of intellectual property - (patents) that is owned by **HALB**. At this point in time, the company holds exclusive licenses for a total of two patents that have been already issued. The company is currently engaged in working across a wide range of

KEY STATISTICS

| | |
|------------------------|-----------------|
| Price as of 12/26/21 | \$0.0172 |
| 52-Week High - Low | \$0.012-\$0.109 |
| Est Shares Outstanding | 511.621M |
| Market Capitalization | \$8.56M |
| Average Volume | 1,708,574 |
| Exchange | OTCQB |

Source: Yahoo Finance / OTC Markets

RECENT NEWS

December 20, 2021, - Halberd Corporation has been able to successfully eliminate Interleukin-2 (IL-2) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Halberd also successfully replicated its previous successful elimination of each of the inflammatory cytokines listed as complete in the table below.

December 15, 2021 - Halberd Corporation (OTC Pink: HALB) has demonstrated 100% eradication of Interleukin-12 (IL-12) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-12 is a pro-inflammatory cytokine which has recently been identified at elevated levels in patients with Alzheimer's Disease or mild cognitive impairment.

December 13, 2021 - Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing. Interleukin-1 is associated with numerous diseases

Halberd Corporation

Ticker: **OTCMKTS:HALB**

Sector: Healthcare
Industry: Biotechnology

Page 2

<https://halberdcorporation.com>

health issues starting from cancer and COVID-19 to CTE (Chronic Traumatic Encephalopathy) and PTSD. These globally occurring medical conditions could open for HALB significant untapped markets in the long run and it is perhaps time for investors to start looking at Halberd Corporation far more closely.

Technical Analysis

These shares formed a top earlier this year at \$0.11 cents before consolidating to current levels. We see minor upside resistance at the \$0.035 and \$0.05 cent levels before testing again the yearly high of 0.11 cents.

Average 30 day volume is 1.8 mill shares / day. Volume continues to exceed that level as these shares advance towards minor resistance. A breakout above the \$0.035 level on increased volume bodes well for a **BREAKOUT** to significantly higher levels.

RECENT NEWS (Contd.)

ranging from autoimmune to Multiple Sclerosis and Alzheimer's Disease. Halberd's demonstrated ability to control the levels of IL-1, coupled with its previous successful elimination of TNF-alpha and other inflammatory cytokines and antigens from CSF, the company believes it has achieved unparalleled progress toward slowing or preventing the onset of Alzheimer's Disease and other disease states.



Management Team

William A. Hartman Chairman of the Board of Directors, President and Chief Executive Officer. From March 2008 until May 2020, Mr. Hartman was President and CEO of Premier Biomedical, Inc. From October 2006 to March 2008, Mr.

Hartman was the Chief Operating Officer of Nanologix, Inc. From July 1991 to July 2000, Mr. Hartman was a Director at TRW Automotive. From 1984 to 1991, Mr. Hartman was Chief Engineer at TRW Automotive and from 1979 to 1984, he was Division Quality Compliance Manager at Ford Motor Company.

At TRW Automotive, Mr. Hartman was one of the auto industry pioneers of the concept of grouping related components into systems and modules and shipping just-in-time to the vehicle assembly plants.

He founded and headed a separate business group within TRW Automotive with plants in the U.S., Mexico and Europe with combined annual sales of \$1.3 Billion. Academic credentials include a BSME degree from Youngstown State University and a MSIA degree (Industrial Administration/Management) from the University of Michigan.

John S. Borza, PE, MBA, VMA is our Chief Operating Officer and a member of our Board of Directors. Prior to May, 2020, Mr. Borza was Executive Vice President and a member of Premier Biomedical's Board of Directors.

Mr. Borza is currently the President and Chief Executive Officer of Value Innovation, LLC, a consulting firm focused on value engineering and creative problem solving, where he has served since August 2009. Prior to Value Innovation, Mr. Borza was a Specialist with TRW Automotive from September 2007 to September 2009, and a Director at TRW Automotive from May 1999 to September 2007.

Earlier in his career, Mr. Borza worked in R&D for 12 years on a variety of products and technologies, in various capacities ranging from Engineer to Chief Engineer, before moving into launch and production support roles.

Mr. Borza is a Registered Professional Engineer (Michigan), an Altshuler Institute certified TRIZ Practitioner, and a SAVE International certified Value Management Associate. He is active in the local chapter of SAVE International. Mr. Borza holds a BS degree in Electrical Engineering and an MBA from the University of Michigan.

Michell S. Felder, MD, is our Chief Technology Officer, Member of the Scientific Advisory Board, and a prolific inventor. He is a Board Certified Neurologist, former Chairman of the Board of Premier Biomedical, former CEO, President, Chairman and founder of Infected and Nanologix.

Dr. Felder acquired a B.A. Degree from the University of Pennsylvania in 1975 and a M.D. Degree from the University of Rome, Faculty of Medicine in 1983. Dr. Felder did his residency at Saint Vincent Hospital in New York, New York, where he was chosen to be Chief Resident in Neurology. He has been Board Certified by both the American Academy of Clinical Neurology and the American Board of Psychiatry and Neurology. Dr. Felder is a Clinical Assistant Professor in the Department of Neurology at the Texas Tech University Health Sciences Center. Dr. Felder has authored or co-authored six publications, three studies and has currently 18 issued patents. Dr. Felder was the Acting Chief of the Department of Neurology, Sharon Regional Health System from 1989 until 2001. Dr. Felder served as the Acting Chief of the Department of Neurology at the William Beaumont Army Medical Center in 2011.

Heidi H. Carl, is our Accounting Director and a member of our Board of Directors. From May of 2009 to May of 2020, Ms. Carl was the Chief Financial Officer and Board Member of Premier Biomedical, Inc.

From June 2007 to May 2009, Heidi was the Product Development Specialist at General Motors Corporation. From May 2006 to May 2007, Heidi was the Associate Marketing Manager at General Motors Corporation. From May 2003 to May 2006, Heidi was the Marketing Specialist at General Motors Corporation and, from May 1999 to May 2003, Heidi was the District Area Parts Manager over 40 dealerships in three states in the southeast at General Motors Corporation. Academic credentials include a BSBA Degree from Madonna University and an ASBA Degree from Oakland Community College.

Healthcare / Medical Industry

The Healthcare / Medical Industry, is composed of a broad range of companies that sell medical products and services. The healthcare sector includes companies that sell drugs, medical devices, and insurance, as well as hospitals and healthcare providers. The XLV index holds some of the largest healthcare companies in the world include United Health Group Inc. 8.5% (UNH), Pfizer Inc.4.8%(PFE), and AbbVie Inc.3.9%(ABBV). Other Companies in the XLV index

Despite this surge in demand for COVID-19 treatments, healthcare stocks have underperformed the broader market. The sector is represented by the Health Care Select Sector SPDR ETF (XLV) . XLV's total return was 23.6% over the past 12 months, below the Russell 1000's total return of 30.4%, as of Nov.24, 2021.

This index has traded as high as 137.04 and as low as 109.37 over the last 52 week period. A breakout above the 135 level is anticipated as we enter the 2d full year of the Covid Pandemic. Protecting and treating billions of people over the next 5 years will be a daunting task for the Healthcare Industry



Patents and Patent Applications

HALB has focused upon developing patented treatments for PTSD, Chronic Traumatic Encephalopathy, and Alzheimer's Disease These three diseases were selected as top priorities, since there are no known cures for these diseases which afflict millions of people worldwide.

The attractiveness of **Halberd's** patented technology is that it is applicable to virtually all diseases through the removal of the pathophysiologic basis (or cause) of the disease by operation on bodily fluids in an extracorporeal manner, whether it be cerebral spinal fluid for neurologic diseases or blood for blood-borne diseases. Because

there are no anticipated side-effects with the inherently safe application methodology associated with Halberd Corporation's extracorporeal process, this could revolutionize medicine.

As mentioned earlier, the lifeblood of an innovative healthcare company like **Halberd** lies in the degree and value of intellectual property it could potentially have under its control. In that regard, the situation looks quite good for **Halberd**. In this section, we are going to look at some of the patent applications that the company has already submitted and the pair of patents that have already been issued to **Halberd**.

First and foremost, we are going to look at the patents for which Halberd has already sent in an application and currently remains in provisional status.

One provisional patent at this point in time is for a 'Method of Treating and Curing COVID-19 Infection'. The application for the same had been placed back on March 16. The second provisional patent is one for a 'Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients'.

Now it is time to take a closer look at the patents which have actually been awarded to the company so far. The first one is for the 'Sequential Extra corporeal Treatment of Bodily Fluids', which had been issued back in 2015. It is a novel method by way of which the bodily fluids of an individual could be treated extra corporeally. It can be deployed in case of all sorts of bodily fluids like blood, lymph, and cerebral spinal fluid. V

The second patent that **Halberd** owns is the one for 'Utilization of Stents for the Treatment of Blood Borne Carcinomas'. The patent had been awarded back in 2014. This method involved a filtering method by way of which blood-borne carcinomas is treated through the inducement of apoptosis in the carcinoma cells.

Patents and Applications List

| # | Title | Patent/ Application No. | Filing Date | Status/Document |
|----|---|-------------------------------|-------------|--|
| 1. | *Method for Treating and Curing Covid-19 Infection | US62/989981 | 03/16/2020 | Application |
| 2. | | PCT/US21/22541 | 03/16/2021 | International PCT995- 004PCT- Application-FINAL.pdf |
| 3. | *Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients | US63/007207 | 04/08/2020 | Provisional Cytokine-provisional- kk,4826-5866-1817.docx |

| | | | | |
|-----|---|---------------------------|------------|--|
| 4. | Covid-19 Inflammatory Cytokine Storm Treatment | PCT/US21/26386 | 04/08/2021 | International PCT995.005_PCT_Imag eFileWrapper_04-08- 2021.pdf |
| 5. | *Method for Treating and Curing Covid-19 Infection by Utilizing a Laser to Eradicate the Virus | US63/013104 | 04/21/2020 | Provisional Laser Method for Treating and CuringCovid,4834-1487- 7370.docx |
| 6. | Treating and Curing Covid-19 Infection Utilizing a Laser | PCT/US21/28368 | 04/21/2021 | International PCT995.006_PCT_Imag eFileWrapper_04-21- 2021.pdf |
| 7. | *Method For The Rapid Identification Of Covid-19 Infection | US63/049441 | 07/08/2020 | Provisional Rapid Covid detection.pdf |
| | | 17370514 | 07/08/2021 | Utility Patent Application |
| 8. | *Nasal Spray To Prevent The Transmission Of Covid-19 Between Humans | US 63/08073517/478,302 | 09/20/2020 | Provisional Application |
| 9. | *Nasal Spray To Prevent The Transmission Of The Covid-19 Virus | US63/108301 | 10/31/2020 | Provisional Nasal Spray to prevent spread prov appl.pdf |
| 10. | *Method For Treating And Curing Covid-19 Infection By Utilizing Radio frequency Extracorporeally To Eradicate The Virus | US63/111043 | 11/08/2020 | Provisional CovidRF eradication.pdf |
| | | | 11/05/2021 | Utility Patent Application |
| 11. | *Monoclonal Antibody For Sars-Cov-2 Spike Protein | US63/116561 | 11/20/2020 | Provisional |
| 12. | *Medication For The Reduction Of Morbidity And Mortality In Person s Infected By Sars- Cov-2 (Covid-19 Virus) | US63/135695 | 01/10/2021 | ProvisionalSpec_2101.pdf |
| 13. | *Extracorporeal Treatment For Aging | US63/193880 | 05/27/2021 | Provisional |

| | | | | |
|-----|--|--------------|------------|------------------------------|
| 14. | *Treating Alzheimer's Disease Utilizing Extracorporeal Radio Frequency | US63/231986 | 07/22/2021 | Provisional |
| 15. | *Treating Alzheimer's Disease Utilizing a Laser | US63/231929 | 08/11/2021 | Provisional |
| 16. | Treating Morbid Obesity Extracorporeally | US63/270387 | 10/21/2021 | Provisional |
| | Utilization of Stents for the Treatment of Blood Borne Carcinomas | US13/128870 | 11/11/2009 | Issued Patent US8,758,287 |
| | Sequential Extracorporeal Treatment of Bodily Fluids | US13/254855 | 3/16/2010 | Issued Patent US9,216,386 |
| | Novel Treatment Method for Cocayne Syndrome | US16/7824486 | 2/05/2020 | Issued Patent US |

*- indicates provisional application.

Investment Highlights

Now that you are well aware of what **Halberd Corporation** actually does as a business and what its intellectual property portfolio looks like, it is perhaps time to take a deeper look at how the company has been conducting its business. In order to do that, it is important for investors to take a look at some of the recent developments with regard to the company. Here is a look at some of the news that investors should keep in mind when analyzing the Halberd stock.

Filing of Additional Extra Corporeal Patent

On November 8, 2021, the company came into focus after it emerged that it had applied for a non-provisional patent with regards to the Extra corporeal treatment for coronavirus infection. The company noted at the time that it was a treatment that could be effective against the different variants of the coronavirus.

Over the course of the year, many new variants of the COVID-19 virus have come into existence and hence, the clamor for treatments for different variants has also gone up. It was a significant move from the company and investors could do well to keep an eye on how the application progresses.

Successfully Eradicates IL-6

Another major development for **Halberd Corporation** came about in November and it is something that investors could consider looking into. Back on November 1, the company announced that it had been successful in eradicating IL-6 in its entirety (that is, by 100%) from synthetic cerebral spinal fluid. It goes without saying that it was a significant development for Halberd and could eventually lead to a major boost for the company in the long run. It should be noted that the total eradication of IL-6 had been achieved in preliminary testing.

In order to achieve this, the company used the Extra corporeal process for which it already holds a process and also deployed the laser eradication procedure, which is currently awaiting a patent.

Obesity Treatment Patent Filing

Even as deadlier diseases continue to spread, obesity has hit chronic proportions over the past years and hence; there are many companies who are now looking into ways to combat the problem. Back on October 25, the company announced that it sent in a provisional patent application with regards to the deployment of its extracorporeal removal process to the United States Patent and Passport Office for the treatment of obesity. In this context, it is also important to have a better idea about the method that Halberd has described in its patent application.

The company has claimed that the extracorporeal removal process can help in removing the cytokines, antigens, and proteins from the blood of individuals. Those are the elements that can cause obesity. It could be a breakthrough obesity treatment and this is something that could be a feather in the cap for **Halberd** if the patent is actually granted.

Another Potential Obesity Cure

It seems that **Halberd Corporation** has decided to make a concerted effort with regards to tackling obesity and back on October 20 the company announced that unrelated research had led to a potential cure for obesity. The company noted that it had been working on research related to cures and treatments for conditions like PTSD and Alzheimer's Disease among others. However, in a remarkable twist, Halberd claimed that during the course of the research, it had managed to unearth a potential cure for obesity.

The research had revealed that the cytokines that can be found in the cerebral spinal fluids of those suffering from a range of neuro degenerative diseases are also present in the blood of those who suffer from obesity. Hence, the company claimed that its treatment could eventually help in bringing about a new age treatment for obesity. This is another thing that investors ought to keep an eye on.

Key Agreement Signed with GTX Corp

A company, especially one that is dependent on constant innovation like **Halberd**, needs to build up fruitful relationships in order to maintain its edge over its peers.

Halberd Corporation has tried to follow the same path as well. The recent weeks have seen a lot of activity at the company and one of the most important developments was the signing of a major agreement with GTX Corp.

Back on October 12, it emerged that **Halberd Corporation** and GTX Corp had reached an agreement with regards to collaboration on the work related to the discovery of cures as well as treatments for a range of neuro degenerative diseases starting from PTSD, CTE, Parkinson's Disease, and Alzheimer's Disease among others. It goes without saying that the agreement in question could unlock considerable value for Halberd in the long run. These are diseases that occur in millions of people and the size of the market is huge.

As per the terms of the agreement, the two companies are going to pool their combined technological prowess and experience in this particular branch of medicine for the purpose of creating treatments for these conditions. However, that is not all.

In addition to scientific collaboration, GTX Corp also signed an agreement for being a reseller of the Vita-Shield-Max™ Immune Support nutraceutical, which is manufactured by Halberd. The product in question is meant for helping in boosting an individual's immunity and following the signing of the agreement, it was going to be made available to customers on the e-commerce website that GTX Corp operates.

Agreement With Helios Dx

The deal-making has been going on a pace at **Halberd Corporation** in recent times and back in September, the company had been in the news after it announced an important agreement with Helios Dx. The

company announced that it signed a scientific collaboration agreement with Helios Dx, which happens to be a fully owned subsidiary company of the Alpharetta-based Rush Net Inc.

The announcement with regards to the deal had been made back on September 22 and it might be a good time for investors to take a closer look at the nature of the deal. The two companies are going to consider working on opportunities and synergies that could prove to be fruitful for both. The most important objective of the collaboration is the development of reliable as well as accurate diagnostic processes through the sharing of new-age technologies and ideas. The two entities believe that such an approach towards a diagnostic method is going to eventually help in better management of diseases.

Major Breakthrough In Alzheimer's Disease Treatment

Back on November 22, the company was in focus once again after it made a major announcement with regards to a finding from its preliminary testing. The company announced that it had managed to eradicate as much as 85% of the total Tumor Necrosis Factor-alpha in cerebral spinal fluid. It was a significant breakthrough for the company considering the fact that Tumor Necrosis Factor-alpha is regarded as a significant factor behind Alzheimer's Disease.

Letter To Shareholders 1-25-22

2021 OVERVIEW AND ACHIEVEMENTS

- Halberd continued its R&D strategy to focus on biomedical areas where:
 1. There is a huge worldwide demand for cures to long standing diseases;
 2. There is no effective cure available;
 3. Big Pharma had either failed to meet that demand or had effectively abandoned the effort; and
 4. Halberd's patent position insured high potential of technical and market success.
- Halberd chose neurodegenerative diseases as its primary focus, since there are approximately 36 million people cumulatively suffering from PTSD/ CTE, Alzheimer's Disease, Lou Gehrig's Disease, Parkinson's Disease, and Epilepsy in the USA alone. The total worldwide is proportionately much higher.
- Halberd's corporate strategy was defined as focusing on completing successful proof-of-concept testing of its patented extracorporeal treatment methodology and subsequently seeking to form joint ventures with Big Pharma organizations and/or university hospital complexes worldwide to secure adequate funding for completion of development testing and regulatory approval prior to market introduction.
- Halberd identified three antigens (Tau, Phosphorylated Tau, & Beta Amyloid), six inflammatory cytokines (IL-1, IL-2, IL-4, IL-6, IL-12, and TNF-Alpha) and one excitatory neurotransmitter (Glutamate) as linked to neurodegenerative diseases; later classified as Halberd's "Top Ten Target Antigens".

Top Ten Neurological Pathogens

Proof of Eradication from CSF Results

| Associated Antigens (Top 10) | PTSD/CTE | Neurodegenerative Diseases* |
|------------------------------|-----------|-----------------------------|
| Phosphorylated Tau | Completed | Completed |
| IL-6 | Completed | Completed |
| TNF- α | Completed | Completed |
| IL-1 | N/A | Completed |
| IL-12 | N/A | Completed |
| IL-2 | N/A | Completed |
| Beta Amyloid | N/A | Completed |
| IL-4 | N/A | Completed |
| Tau | N/A | 1Q22 |
| Glutamate | 1Q22 | 1Q22 |

N/A – indicates antigen is not associated with listed condition.

* – Includes Alzheimer's, Parkinson's, Epilepsy & Lou Gehrig's Diseases

- Halberd developed a proprietary process to conjoin metallic nanoparticles to proprietary antibodies, forming a two-part metallic moiety. After joining the metallic moiety to the antigens, eradication of the antibody-antigen complex is accomplished via laser emissive energy or radio frequency exposure.
- Halberd successfully completed work on eradicating 100% of all eight of the Top Ten target antigens tested so far linked to neurodegenerative diseases. Eradication of Halberd's remaining two Target Antigens has been delayed by lack of availability of commercial reagent supplies from worldwide sources.
- The principal competitive Alzheimer's drug treatment available today eliminates 5-15% of Beta Amyloid after one month of treatment costing over \$50,000 per year. Halberd's extracorporeal process eradicates 100% within just 10 minutes.
- Meetings have been held with representatives from the NFL Retired Players Association (NFLPA) to develop a strategy for presenting our results to NFL management to seek their support for ongoing research toward developing a cure for PTSD/CTE. Meetings have not yet been established with NFL management.
- Halberd added an expert Nephrologist to its staff in anticipation of blood-borne tests, slated to get underway after completion of testing in cerebral spinal fluid (CSF).
- One issued patent has been added this year to Halberd's IP for the extracorporeal treatment of disease, bringing the total to three related issued patents. Additionally, Halberd added several provisional patent applications bringing that total to twenty. Halberd is working hard to protect its intellectual property to prevent potential theft and/or duplication by competitors.
- Halberd Corp. commenced an independent audit in the fourth quarter to work towards its planned FORM-10 application to achieve fully reporting status with the SEC under the Exchange Act of 1934.
- Halberd has been approved as a governmental contractor making it eligible to participate in development grants, and is currently awaiting a decision on such a potential large government grant associated with PTSD/CTE.

FORWARD GOALS

- Halberd's on-going independent audit is anticipated to be completed within Q1 2022.
- Efforts are underway on filing Halberd's FORM-10 contingent on the completion of its independent audit leading to OTCQX exchange up-list by or within Q2 2022.
- Completion of the Top Ten Target Antigen elimination from CSF is expected to be completed within Q1 2022.
- Establish and execute meetings with the NFL and possibly the NCAA to seek endorsement for Halberd's PTSD/CTE research.
- Halberd plans on further expanding brand recognition and outreach by communicating with investors and the public via appearances on New-To-The-Street, Money TV, Stock Day Podcast along with periodic press releases and email blasts to our subscribers to provide visibility on our progress.

- Discussions have commenced and are in progress with a large medical university to develop potential cures for several neurodegenerative diseases with potential independent validation within the year 2022. We plan on sharing the name of this university once an agreement is established.
- We are looking into conducting initial discussions with an identified pharmaceutical company for potential partnering arrangements.
- The next steps in Halberd's R&D program include eradication of the "Top Ten Target Antigens" from blood elements (serum and plasma).
- Plans are underway for generating scientific articles for publication within Q1 2022. The material will be carefully screened for patentable content prior to publication to protect our intellectual property and achievements.
- Halberd is currently searching for an infectious disease specialist to be added to its company staff within Q1 2022 to assist in developing and testing cures for infectious diseases which have the potential of being treated with Halberd's proprietary technology.
- Halberd plans to expand its over-the-counter (OTC) supplement product line with a brain function support product. The brain function support product is currently being formulated and designed. We plan on sharing updates as we progress.
- Halberd will continue its efforts in developing relationships toward placing and marketing its nutraceutical line products in both Central and South America to increase both brand recognition and revenue.
- Conclude current ongoing talks with a major university to acquire related abandoned intellectual property that could expand Halberd's value significantly.
- Continue to protect Halberd's intellectual property by timely filing of patent applications.

SUMMARY

In summary, the Halberd team is expanding its technical capabilities and has exhibited solid progress in 2021. We believe our strategy going forward is exciting and will lead to success for the company and our stockholders/shareholders in 2022 and beyond.

We look forward to a healthy, happy and prosperous 2022 for all.

Sincerely,

William A. Hartman
Chairman, President & CEO
HALBERD CORPORATION
w.hartman@halberdcorporation.com;
support@halberdcorporation.com
www.halberdcorporation.com

Corporate Update

Halberd's technology is incorporated into three issued U.S. Patents covering extracorporeal treatment of disease, and 16 related provisional patent applications. Halberd decided to initiate its patented treatment process on E. coli bacteria, since it was readily available, non-pathogenic, and is the leading cause of meningitis in children and blood sepsis in adults, which collectively are responsible for the deaths of $\frac{3}{4}$ of a million Americans each year.

The attractiveness of **Halberd's** patented technology is that it is applicable to virtually all diseases through the removal of the pathophysiologic basis (or cause) of the disease by operation on bodily fluids in an extracorporeal manner, whether it be cerebral spinal fluid for neurologic diseases or blood for blood-borne diseases. Because there are no anticipated side-effects with the inherently safe application methodology associated with Halberd Corporation's extracorporeal process, this could revolutionize medicine. Mitchell S. Felder, M.D., the co-inventor of this innovative technology, and the Chief Technology Officer of

Halberd Corporation stated, "More than one out of four people on earth are destined to die from an infectious disease. Imagine a world where there is no threat from any infectious disease: no Covid-19, no malaria, no tuberculosis, no sepsis, no meningitis, no pandemics. The successful experimentation we have conducted in collaboration with **Youngstown State University (YSU)** and **Arizona State University (ASU)**, may serve as the first step to an elegant solution to these worldwide tragedies."

"By implementing our patent-pending extra-corporeal laser methodology, combined with the three granted U.S. patents of **Halberd**, along with the multiple provisional patent applications, eradicating infectious diseases, among many other afflictions, could become a reality."

Felder continued, "Our method envisions utilizing a dialysis variation in which blood or cerebral spinal fluid (CSF) are briefly removed from a patient, through a catheter, and then combined with antibodies which contain a metallic complex. The bodily fluid (blood or CSF) is then exposed to a laser or radio frequency (RF) energy, which kills the infectious pathogen. The cleansed (pathogen-/infection-free) bodily fluid is returned to the patient. Obviously, there will never be successful resistance by any infectious bacteria, virus or mutations, fungus or amoeba to a laser. This is entirely accomplished extracorporeally and without exposing the body to the effects of a laser."

PTSD, Chronic Traumatic Encephalopathy, and Alzheimer's Disease were selected as our top priority focus, since there are no known cures for these diseases which afflict millions of people worldwide. To our knowledge there is no credible treatment in existence which addresses the removal of the source of the neurofibrillary tangles and plaques associated with Alzheimer's Disease.

Making it a more daunting task for conventional approaches is the fact that it features a multiplicity of contributing antigens, inflammatory cytokines

and an excitatory neurotransmitter in the form of excessive levels of Glutamate involved in Alzheimer's Disease.

Halberd has successfully eradicated Phosphorylated Tau (the principal basis for neurofibrillary tangles), IL-6 (a major factor in PTSD, CTE, and cancer), TNF-Alpha (a major factor in PTSD and CTE), and we are currently working on Glutamate (a major factor in all neurodegenerative diseases, including Epilepsy and Lou Gehrig's Disease).

As soon as **Halberd** is successful in eradicating the appropriate amount of Glutamate, it will have completed its short-term goal of establishing proof of concept toward finding a cure for PTSD/CTE and intends to approach the military, the NFL, and the NCAA to seek support/endorsement for our continuing program. Next, Halberd will pursue its the long-term goal of developing a cure for Alzheimer's Disease, and Parkinson's Disease.

Halberd's strategy continues to follow its process road map consisting of the following steps:
Identifying a target antigen; (or in the case of Alzheimer's disease, three antigens, six inflammatory cytokines; and an excitatory neurotransmitter (Glutamate);

Creating patentable antibodies with high binding affinity against the target antigen(s);

Conjugating these antibodies with metallic nanoparticles (moieties) through our patent-pending process;

Applying Halberd's patented extracorporeal process of eradicating the nanoparticle-antibody-antigen complex in bodily fluids through the patent-pending process of exposing it to radiofrequency waves or laser emissive energy, or other means;

Conducting animal testing to establish the safety and efficacy of our revolutionary process for the eradication of diseases.

And finally, human testing, FDA certification, and implementation to eradicate the disease state.

We have successfully completed steps 1, 2, & 3 for both E. coli and select PTSD/CTE and Alzheimer's Disease pathogens. We are in the process of executing Step 4 for effectiveness against both E. coli bacteria as well as neurodegenerative diseases.

Halberd is convinced that once the first five steps are completed for the removal of the major antigens which have been linked to the neurofibrillary tangles and plaques associated with Alzheimer's Disease, Halberd will be positioned to negotiate joint ventures and/or licensing agreements with a selected major biotechnology company which could aid in facilitating the process to complete certification by the FDA and other regulatory agencies around the world.

These accomplishments will also better position Halberd for more substantial charitable contributions. Halberd

has applied for a sizable government grant, and we have received notice that our application white paper has been accepted by the Department of Defense. We expect to receive tranches toward that grant early in 2022.

William A. Hartman, Halberd's Chairman, President & CEO, stated, "This is a clear breakthrough in the eradication of disease. Our extensive review of medical research reports reveals no other successful use of a laser for pathogen eradication. Over the last several weeks, we have applied what we learned in the E. coli experiments and have eliminated several of the disease antigens which contribute to Alzheimer's Disease and PTSD from Cerebral Spinal Fluid.

In parallel, we conducted RF exposure disease-elimination experiments. Our RF test results have mirrored the results experienced during our laser tests. Having alternative treatment methods will offer health care professionals the flexibility to select the most suitable approach for each patient, disease condition and environment. Following our experiments with CSF, Halberd plans to conduct similar tests with target disease antigens in blood plasma for blood-borne diseases."

People Inflicted With Various Disease - BELOW

24.5 million with PTSD/CTE6.

3 million with Alzheimer's Disease in the USA and 40 million worldwide

Parkinson's Disease 1.0 million / Multiple Sclerosis - 400,000 Lou Gehrig's Disease

30,000 Huntington's Disease - 30,000 / Epilepsy - 3.4 million

Conclusion

Halbred Corporation has what we think is a unique approach among other things to curing disease through the cleansing of bodily fluids through extra-corporeal laser methodology. In association with the medical research staff at **Arizona State University** and **Youngstown State University**, **Halberd's** management team has moved much closer to delivering new and cutting edge procedures for curing worldwide health issues.

We feel that such patents on these important and significant medical procedures using laser treatments on blood, spinal fluids, and other sections of the human body add significant value to **Halbred's** portfolio of patents.

Given these significant values - revenues that these patents could generate going forward into the future, we feel that the shares of **HALB** are **significantly undervalued**. These shares are trading close to their yearly low and we have seen rallies to a **high of \$0.10 cents**. The opportunity exists for significant upside movement should any one of **HALB's** many patents prove to become successful and marketable.

Latest Press

Tue Feb 1st, 2022

Halberd Achieves Landmark Selective Elimination of Tau From an Antigen Mixture

Tue Jan 25th, 2022

Halberd CEO Letter: 2021 Year-End & 2022 Outlook

Thu Jan 13th, 2022

Halberd, Inc. (HALB) Reports Elimination of Target Antigens, Progressing to Treatments for Neurodegenerative Diseases

Wed Jan 5th, 2022

Halberd Corporation Now an Official US Government Contractor

Mon Dec 20th, 2021

Halberd Moves Closer to Proving Its Patented Technologies Eliminate Contributors to Neurodegenerative Diseases

Wed Dec 15th, 2021

Halberd Eradicates Another Inflammatory Cytokine, Interleukin-12, In Its Continuing Effort To Eliminate Neurodegenerative Diseases

Mon Dec 13th, 2021

Halberd Successfully Eradicates Interleukin-1 in Its Continued Progress Toward Eliminating Neurodegenerative Diseases